With GSK's €1.4Bn investment into acquiring CureVac's infectious disease pipeline, Moderna and BioNTech's initiation of personalised cancer vaccine trials, and the emergence of novel mRNA applications in protein replacement therapy, gene editing and in vivo cell engineering, the mRNA industry is observing huge value R and D opportunities that will open the floodgates towards clinical and market approval in 2025.
The 4th mRNA-Based Therapeutics Summit Europe returns to Frankfurt, Germany as the industry's premier forum dedicated to showcasing the hottest disease targets, never-before-seen pre-clinical and clinical data, and demonstrating key routes to commercial success for mRNA therapy and vaccine R and D pipelines.
Whether you're entering the mRNA arena for the first time or a well-seasoned mRNA veteran, with two dedicated tracks of content spanning discovery through commercialisation, this forum will equip you with the know-how and connections to make rapid advances in your work with partnering and collaborative networking opportunities spread throughout.
Assembling 200+ mRNA enthusiasts from across Europe, Asia and the globe, this is your one-stop-shop to gain unparalleled overview of cutting-edge R and D innovations, whilst diving deep into end-to-end development strategy
...
afficher plus
With GSK's €1.4Bn investment into acquiring CureVac's infectious disease pipeline, Moderna and BioNTech's initiation of personalised cancer vaccine trials, and the emergence of novel mRNA applications in protein replacement therapy, gene editing and in vivo cell engineering, the mRNA industry is observing huge value R and D opportunities that will open the floodgates towards clinical and market approval in 2025.
The 4th mRNA-Based Therapeutics Summit Europe returns to Frankfurt, Germany as the industry's premier forum dedicated to showcasing the hottest disease targets, never-before-seen pre-clinical and clinical data, and demonstrating key routes to commercial success for mRNA therapy and vaccine R and D pipelines.
Whether you're entering the mRNA arena for the first time or a well-seasoned mRNA veteran, with two dedicated tracks of content spanning discovery through commercialisation, this forum will equip you with the know-how and connections to make rapid advances in your work with partnering and collaborative networking opportunities spread throughout.
Assembling 200+ mRNA enthusiasts from across Europe, Asia and the globe, this is your one-stop-shop to gain unparalleled overview of cutting-edge R and D innovations, whilst diving deep into end-to-end development strategy to revolutionise the next wave of mRNA medicines towards clinical reality.
Brochure: https://go.evvnt.com/2674553-3?pid=1356
Speakers: Alexander Zehnder Chief Executive Officer CureVac, Ansgar Santel Chief Executive Officer Pantherna Therapeutics, Bo Ying Chief Executive Officer Abogen Biosciences, Gilles Divitas Chief Executive Officer Divincell, Jenny van Asbeck – van der Wijst Chief Executive Officer Mercurna, Nicolas Poirier Chief Executive Officer OSE Immunotherapeutics, Xiangrong Song Co-Founder and General Manager WestGene Biopharma, Julia Djonova Head Division Advanced Therapy Medicinal Products, Swiss Agency for Therapeutic Products, Swissmedic Swissmedic, Maren von Fritschen Head of Regulatory Policy Moderna, Ruben Rizzi Senior Vice President Global Regulatory Affairs BioNTech AG, Shirley Hopper Deputy Director National Licensing Strategy Medicines and Healthcare products Regulatory Agency, Adèle Schmitt Expert Scientist GSK, Albert Kwok Co-Founder and Chief Scientific Officer Nuntius Therapeutics, Amin Khan Chief Science Advisor, WHO MRNA Program Afrigen Biologics (Pty) Ltd, Caryn Fenner Executive Director - Messenger Ribonucleic Acid Hub Afrigen Biologics (Pty) Ltd, Chijian Zuo Vice President CureMed Biomedical Technology, Christian Dohmen Executive Director - Technology Development, Chemistry, Manufacturing, and Controls Ethris, Daniel Tondera Head of Biology Pantherna Therapeutics, Dr. Myriam Mendila Chief Scientific Officer and Head of R and D CureVac, German Sanchez Alberti Development and Innovation Manager Sinergium Biotech, James Lee Senior Director - Search and Evaluation Everest Medicines, Jing Zhu Vice President and Head of Process Development ReciBioPharm, Jingsong Cao Senior Fellow, Research and Discovery Innorna Co. Ltd, Marie Caby-Tosi Executive Director, EU/UK QPPV Moderna, Nigel Horscroft Chief Technology Officer Stealth Mode mRNA Biotech, Pierre Wils Global Scientific Advisory Lead - mRNA Centre of Excellence Sanofi, Thomas Langenickel Chief Medical Officer Ethris GmbH, Verena Mummert Director - Alliance Management Ethris, Vincent Serra Chief Scientific and Operating Officer Neovacs, Yeong-Chan Ahn Senior Manager sml biopharm, Zach Zhu Chief Technology Officer Innorna, Lyudmila Kovalchuke Project Manager VIB-UGent Center for Medical Biotechnology, Marcus Wilhelmsson Professor of Physical Chemistry Chalmers University of Technology, Miguel Seabra Professor Champalimaud Foundation, Neill Liptrott Professor of Pharmacology and Therapeutics University of Liverpool, Philippe Menasche Professor - Thoracic and Cardiovascular Surgery University of Paris-Cité, Raymond Schiffelers Professor of Nanomedicine Utrecht University, Roland Brock Professor of Biochemistry Radboud University Medical Center, Samir El-Andaloussi Professor of Biomolecular Medicine and Advanced Therapy and Co-Founder Karolinska Institutet and Evox Therapeutics, Zoltán Kis Associate Professor – Department of Chemical and Biological Engineering University of Sheffield
Prices:
Drug Developer Pricing - Conference and Workshop Day: EUR 4446.00,
Drug Developer Pricing - Conference Only: EUR 2799.00,
Academic Pricing - Conference and Workshop Day: EUR 3746.00,
Academic Pricing - Conference Only: EUR 2399.00,
Service Provider Pricing - Conference and Workshop Day: EUR 5446.00,
Service Provider Pricing - Conference Only: EUR 3499.00
Venue details: Sheraton Frankfurt Airport Hotel and Conference Center, 15 Hugo-Eckener-Ring, Frankfurt am Main, Hessen, 60549, Germany
afficher moins
